These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. Its proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. Tito Serafini, Chief Executive Officer and Co-Founder, Atreca develops novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. Atreca’s proprietary Immune Repertoire Capture technology profiles a patient’s immune response at the single-cell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The company intends to use the funds for the further development and advancement of its product pipeline, including therapeutic antibodies designed to optimize anti-tumor immune responses in synergy with checkpoint inhibitors and immune activators. The round was led by a large U.S.-based, healthcare-focused fund with participation from the Bill & Melinda Gates Foundation, Mission Bay Capital, and GlaxoSmithKline. ![]() Atreca, Inc., a Redwood City, CA-based biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, completed its $56m Series A funding. Atreca, Inc. Profiling of T- and B-cell receptor repertoires in an individual has led to a vast repository of information on acquired immunity against various microorganisms.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |